pioglitazone has been researched along with Lipodystrophy, Familial Partial in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Lipodystrophy, Familial Partial: Inherited conditions characterized by the partial loss of ADIPOSE TISSUE, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of SUBCUTANEOUS FAT from the limbs and trunk (type 2). Type 3 is associated with mutation in the gene encoding PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 7.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 3.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "The laminopathy variant familial partial lipodystrophy type 2 or Dunnigan syndrome (FPLD2) is the most common cause of partial LD." | 1.42 | [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia]. ( Kalashnikova, MF; Melnichenko, GA; Sorkina, EL; Tyulpakov, AN, 2015) |
| "Pioglitazone was markedly effective in glycemic control in this case." | 1.35 | Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. ( Chen, W; Ebihara, K; Hosoda, K; Ito, J; Iwanishi, M; Kusakabe, T; Masuzaki, H; Nakao, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Iizaka, T | 1 |
| Kodama, E | 1 |
| Mikura, K | 1 |
| Iida, T | 1 |
| Imai, H | 1 |
| Hashizume, M | 1 |
| Kigawa, Y | 1 |
| Sugisawa, C | 1 |
| Tadokoro, R | 1 |
| Endo, K | 1 |
| Otsuka, F | 1 |
| Isoda, M | 1 |
| Ebihara, K | 2 |
| Ishibashi, S | 1 |
| Nagasaka, S | 1 |
| Agostini, M | 1 |
| Schoenmakers, E | 1 |
| Beig, J | 1 |
| Fairall, L | 1 |
| Szatmari, I | 1 |
| Rajanayagam, O | 1 |
| Muskett, FW | 1 |
| Adams, C | 1 |
| Marais, AD | 1 |
| O'Rahilly, S | 2 |
| Semple, RK | 1 |
| Nagy, L | 1 |
| Majithia, AR | 1 |
| Schwabe, JWR | 1 |
| Blom, DJ | 1 |
| Murphy, R | 1 |
| Chatterjee, K | 2 |
| Savage, DB | 2 |
| Sorkina, EL | 1 |
| Kalashnikova, MF | 1 |
| Melnichenko, GA | 1 |
| Tyulpakov, AN | 1 |
| Tan, GD | 1 |
| Fielding, BA | 1 |
| Collins, J | 1 |
| Hodson, L | 1 |
| Humphreys, SM | 1 |
| Frayn, KN | 1 |
| Karpe, F | 1 |
| Valizadeh, N | 1 |
| Tehrani, MR | 1 |
| Amoli, MM | 1 |
| Bandarian, F | 1 |
| Collet-Gaudillat, C | 1 |
| Billon-Bancel, A | 1 |
| Beressi, JP | 1 |
| Iwanishi, M | 1 |
| Kusakabe, T | 1 |
| Chen, W | 1 |
| Ito, J | 1 |
| Masuzaki, H | 1 |
| Hosoda, K | 1 |
| Nakao, K | 1 |
| Moreau, F | 1 |
| Boullu-Sanchis, S | 1 |
| Vigouroux, C | 1 |
| Lucescu, C | 1 |
| Lascols, O | 1 |
| Sapin, R | 1 |
| Ruimy, D | 1 |
| Guerci, B | 1 |
| Pinget, M | 1 |
| Jeandidier, N | 1 |
| Sleilati, GG | 1 |
| Leff, T | 1 |
| Bonnett, JW | 1 |
| Hegele, RA | 1 |
9 other studies available for pioglitazone and Lipodystrophy, Familial Partial
| Article | Year |
|---|---|
Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
Topics: Adiponectin; Adult; Diabetes Mellitus; East Asian People; Female; Humans; Insulin Resistance; Lipody | 2023 |
A Pharmacogenetic Approach to the Treatment of Patients With
Topics: Adolescent; Adult; Amino Acid Substitution; Binding Sites; Female; Gene Expression Regulation; Genes | 2018 |
[Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
Topics: Caloric Restriction; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance; Lamin Type | 2015 |
Fatty acid metabolism in patients with PPARgamma mutations.
Topics: Adipose Tissue; Adult; Amino Acid Substitution; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, | 2008 |
Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
Topics: Acanthosis Nigricans; Adolescent; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; | 2008 |
Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
Topics: Adipose Tissue; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2009 |
Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
Topics: Absorptiometry, Photon; Adiponectin; Adiposity; Blood Glucose; Body Composition; Diabetes Complicati | 2009 |
Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.
Topics: Adipose Tissue; Adult; Body Mass Index; Body Size; Female; Humans; Hypoglycemic Agents; Lipodystroph | 2007 |
Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
Topics: Adult; Clofibric Acid; Female; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy, Familial Partial | 2007 |